Quote from michaelscott:
This concerns me too.
The first concern is that its a small cap pharmy and we all know what can happen to these things with one wrong announcement. Fortunately, I dont see any huge gap downs in the last few years so I think we might be safe.
Secondly, this reached a high in late January and then lost momentum from there. While the market has been going straight up since the February correction, SVNT has been drifting downward making lower highs and lower lows.
Unfortunately Cramer came out in January with SVNT as one of his top 3 speculative picks in 2007 so that in part fueled the run above $15. It was ahead of itself at that time. Pullback was expected IMO.
The Phase 3 should wrap up late summer or early fall, within the 6 months your original post specified. Required endpoints of the trial are same as Phase 2 and they have a SPA.
I think it can see $20 by fall and $25 by year end assuming no surprises in Phase 3. Probability of success is 90% or so IMO.
Last, I've traded SVNT (formerly BTGC) since 1998 and it can be a decent trading stock.

